Jeffrey Robert Ajer - Jan 25, 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Commercial Officer
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Jan 25, 2023
Transactions value $
-$2,346,444
Form type
4
Date filed
1/27/2023, 08:35 PM
Previous filing
Nov 4, 2022
Next filing
Mar 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $3.32M +49K +119.26% $67.81 90.1K Jan 25, 2023 Direct F1
transaction BMRN Common Stock Sale -$5.18M -44.8K -49.76% $115.65 45.3K Jan 25, 2023 Direct F1, F2
transaction BMRN Common Stock Sale -$485K -4.18K -9.22% $116.15 41.1K Jan 25, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -2.2K -100% $0.00* 0 Jan 25, 2023 Common Stock 2.2K $67.81 Direct F1, F4
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -46.8K -100% $0.00* 0 Jan 25, 2023 Common Stock 46.8K $67.81 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on February 28, 2022.
F2 The price in column 4 is the weighted average price. The price actually received ranged from $115.000 to 115.998. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F3 The price in column 4 is the weighted average price. The price actually received ranged from $116.000 to $116.485. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F4 Reflects the number of options outstanding after the transactions from this specific stock option grant.